Cigna Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Cigna Group (NYSE: CI) gives CEO new stock options and restricted shares vesting from 2027 - Stock Titan

AI-generated analysis

πŸ“… Cigna Group CEO Brian C. Evanko received new equity awards on September 1, 2026.

πŸ“ˆ He was granted 6,716 stock options with an exercise price of $281.1325 per share.

πŸ”’ A separate award of 3,113 restricted shares was also granted to the CEO.

⏳ Both the options and restricted shares vest in three equal annual installments starting September 1, 2027.

πŸ’Ό After the grants, Evanko holds 41,030 common shares directly and additional indirect holdings.

🚫 The filing confirms no Rule 10b5-1 trading plan was used for these specific transactions.

Bullish Signals
  • Cigna Group has granted significant equity compensation to its CEO, aligning executive interests with long-term shareholder performance and retention goals.
  • The substantial increase in insider ownership demonstrates management's confidence in the company's future prospects and commitment to retaining top leadership.
Risk Factors
  • The grant of 6,716 stock options represents a potential source of future dilution for existing shareholders upon exercise.
  • The restricted shares are subject to a three-year vesting schedule, limiting immediate liquidity and creating a lock-up period for the insider.
Full Analysis
Cigna Group (CI) reported that its President and Chief Executive Officer, Brian C. Evanko, received new equity awards on September 1, 2026. The compensation package included the grant of 6,716 stock options with an exercise price of $281.1325 per share and a separate award of 3,113 restricted shares of common stock. Both the stock options and the restricted shares are scheduled to vest in three equal annual installments beginning September 1, 2027. Following these grants, Evanko holds 41,030 common shares directly, plus indirect holdings of 25,614 shares through a GRAT and 919.5791 shares through the company's 401(k) Plan. The filing indicates that no Rule 10b5-1 trading plan was in place for these transactions. These equity grants align executive incentives with long-term shareholder value, though they represent future dilution potential upon option exercise and add to the insider ownership structure of the insurer.